Hormonal
Insulin manipulation (restriction) to control weight in Type 1 Diabetes leads to chronic hyperglycemia, increased morbidity, and a threefold increase in relative risk of death.
If you have Type 1 Diabetes, never restrict your insulin to lose weight. This practice, known as 'diabulimia,' causes severe health complications and triples your risk of death. If you are struggling with body image or weight, seek help from a mental health professional or a diabetes specialist who can help you manage your weight safely without compromising your blood sugar.
Strategic insulin restriction as a means of 'calorie purging' to prevent weight gain causes chronic hyperglycemia... Insulin manipulation behaviors lead to an increase in morbidity as evidenced by a threefold increase in relative risk of death for individuals who restrict insulin.
Why this rating
Supported by registry data and specific studies on insulin manipulation prevalence and outcomes.
Source
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Karen D. Corbin et al. · Endocrine Reviews · 2018
DOI 10.1210/er.2017-00191
More from this paper
- Intensive insulin therapy in Type 1 Diabetes causes significant weight gain, which subsequently increases the risk of cardiovascular disease and metabolic complications.Good
- Adjunctive therapies such as pramlintide, metformin, and GLP-1 receptor agonists can improve glycemic control and promote weight loss or weight neutrality in Type 1 Diabetes when added to insulin therapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →